rcca-header
Clinical Trials

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies
Phase
Division (Location)
Bethesda, MD
Study ID
NCT#
Brief Description
A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.